Halozyme Therapeutics, Inc. (HALO)
110.75
+1.09
(+0.99%)
USD |
NASDAQ |
Sep 03, 16:00
110.75
0.00 (0.00%)
After-Hours: 20:00
Halozyme Therapeutics Research and Development Expense (TTM) : 102.37M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 102.37M |
| March 31, 2026 | 92.25M |
| December 31, 2025 | 81.49M |
| September 30, 2025 | 70.03M |
| June 30, 2025 | 71.24M |
| March 31, 2025 | 74.74M |
| December 31, 2024 | 79.05M |
| September 30, 2024 | 79.94M |
| June 30, 2024 | 78.81M |
| March 31, 2024 | 77.50M |
| December 31, 2023 | 76.36M |
| September 30, 2023 | 77.59M |
| June 30, 2023 | 76.98M |
| March 31, 2023 | 72.73M |
| December 31, 2022 | 66.61M |
| September 30, 2022 | 54.15M |
| June 30, 2022 | 45.93M |
| March 31, 2022 | 38.52M |
| December 31, 2021 | 35.67M |
| September 30, 2021 | 32.94M |
| June 30, 2021 | 32.20M |
| March 31, 2021 | 33.09M |
| December 31, 2020 | 34.24M |
| September 30, 2020 | 54.77M |
| June 30, 2020 | 77.47M |
| Date | Value |
|---|---|
| March 31, 2020 | 101.43M |
| December 31, 2019 | 122.60M |
| September 30, 2019 | 131.34M |
| June 30, 2019 | 136.43M |
| March 31, 2019 | 143.60M |
| December 31, 2018 | 150.25M |
| September 30, 2018 | 154.98M |
| June 30, 2018 | 153.43M |
| March 31, 2018 | 151.68M |
| December 31, 2017 | 150.64M |
| September 30, 2017 | 150.62M |
| June 30, 2017 | 150.49M |
| March 31, 2017 | 147.68M |
| December 31, 2016 | 150.84M |
| September 30, 2016 | 137.24M |
| June 30, 2016 | 130.99M |
| March 31, 2016 | 116.65M |
| December 31, 2015 | 93.24M |
| September 30, 2015 | 85.22M |
| June 30, 2015 | 77.51M |
| March 31, 2015 | 74.96M |
| December 31, 2014 | 79.70M |
| September 30, 2014 | 80.89M |
| June 30, 2014 | 86.68M |
| March 31, 2014 | 96.02M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Incyte Corp. | 2.098B |
| AVITA Medical, Inc. | 20.15M |
| Neurocrine Biosciences, Inc. | 1.131B |
| Iovance Biotherapeutics, Inc. | 267.71M |
| Editas Medicine, Inc. | 82.53M |